Category: Healthcare Industry

Amgen updates agreement with DaVita for dialysis treatment

Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico.

Sydney toddler becomes youngest child to receive blood from her own …

Toddler, 20 months, becomes youngest child in the world to receive blood from her own UMBILICAL CORD to stop diabetes – after it was stored to treat her sister for the same disease A Sydney toddler whose umbilical cord blood was stored to help treat her sister’s Type 1 diabetes has had it reinfused after showing signs of the disease herself. Lucy Hinchion, aged 20 months, on Friday became the youngest child in the world to receive her own cord blood to help prevent or delay the chronic condition’s onset, as part of a five-year study at The Children’s Hospital in Westmead.

BioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2017 — BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that Health Canada has approved RAPIVAB i 1 2 , an intravenous treatment for acute, uncomplicated influenza.i 1 2 RAPIVAB is approved by the U.S. Food & Drug Administration and is also licensed for use in Japan and Taiwan as RAPIACTAi 1 2 and in Korea as PeramiFlui 1 2.i 1 2 i 1 2This RAPIVAB approval represents an important milestone for BioCryst and for our partner, Seqirus,i 1 2 said Jon P. Stonehouse, President & Chief Executive Officer .i 1 2 i 1 2We are excited that patients in Canada will soon have an I.V. option for the treatment of influenza infections.i 1 2i 1 2 RAPIVAB is being commercialized by Seqirus globally, excluding Japan, Taiwan, Korea and Israel.i 1 2 Seqirus is a … (more)

A Woman’s Heart event scheduled for Feb. 2

Cookeville Regional Medical Center’s “A Woman’s Heart” event committee is in full swing planning the Heart Fund’s biggest fundraiser of the year. Looking forward to the A Woman’s Heart event are, in front, from left, committee members Margaret Arseniadis, Hannah Davis, and Sylvia Kennedy; Katelyn Steakley, Bless Boutique; committee members Marcy Griffin, Cherry Ramsey, chair Coleen Schabacker and Leah Ingram; and Foundation director John Bell; and in back, committee members Amanda Scott, Debbie Baker, Elizabeth Kase; Emily Carwile, Matilda Jane clothing; and committee members Amy Rich, Tracy Galyean, Paula Jackson and Barb Davis.

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer

Sales of Regeneron’s lead product have been tapering off, but a handful of potential blockbusters could provide some big gains in 2017 and beyond. The pharma giant, meanwhile, also has some exciting growth drivers in its lineup, but an aging product line will make big gains difficult going forward.

NeuroMetrix to Present at the Digital Medicine Showcase 2017: At the…

NeuroMetrix, Inc. today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Digital Medicine Showcase 2017 at the Parc 55 San Francisco in San Francisco, . The Digital Medicine Showcase brings together innovative companies showcasing clinically impactful digital health technologies, venture capital and private equity investors, pharma executives and professional advisors.

HRMC limits hospital visitation due to flu-like illnesses

Effective immediately, Haywood Regional Medical Center will begin “limited visitation” at the hospital due to the increased number of positive flu cases in our area and increased number of admissions. The rates of influenza-like illness have risen above the two percent mark in our region and the flu has been responsible for the deaths of four people in the state already.

Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year

Despite a generally bleak year for Gilead, and for biotech stocks in general, shares of Exelixis, Inc. Can these biotechs continue climbing throughout the new year and beyond, or are they about to sputter and run out of fuel? Let’s look at what’s propelling them upward to see why they might be better picks than Gilead Sciences. A string of good news for Exelixis’ lead cancer drug made this one of the best-performing biotech stocks of 2016.

Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals

Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals In 2016, these two stocks have taken paths as varied as their approaches to drug development, and the past few months have been a wild ride.

Can you really die of a broken heart?

… in women – by people with a history of neurologic problems, such as seizures, and by people with a history of mental health problems. Though a stress-based theory is probably correct, the precise cause of the syndrome remains unknown, according to …

article

… and Opko’s longer-lasting candidate might have performed even better with a more convenient dosing schedule. Opko Health isn’t throwing in the towel just yet. Although hGH-CTP failed to significantly reduce trunk fat mass compared to a placebo after …

Read Story

… by women, by people with a history of neurologic problems, such as seizures, and by people with a history of mental health problems. “What is known from large studies of Takotsubo is that 90 percent of cases are in women,” Campbell said, adding that …

Mylan launches generic Zovia in U.S.

Mylan has announced the launch of a generic version of Zovia , a pregnancy preventative, in the U.S. The product — Ethyniol Diacetate and Ethinyl Estradiol tablets — was found to be bioequivalent to Zovia, and subsidiary Jai Pharma got FDA approval for its abbreviated new drug application.

FDA puts Seattle Genetics drug trials on hold after 4 deaths

Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies. Six patients with acute myeloid leukemia , a type of blood cancer, have been identified with liver toxicity and four have died, the company said on Tuesday.

Top Insider Buys of the Week

… share. The price of the stock has decreased by 0.13% since. Abbott Laboratories is an American-based international health care company. It has more than 74,000 employees in 150 countries. Some products include pharmaceutical drugs, medical devices …

PTAB Upholds Validity of BMS Patent

The PTAB issued a Final Written Decision upholding the validity of Bristol-Myers Squibb’s U.S. Patent 8,476,239, which had been challenged by Momenta in IPR2015-01537. According to documents filed with the PTAB during the IPR, the ‘239 patent covers stable formulations of a protein called “CTLA4Ig.”

Impax Laboratories Is Undervalued

Investors in the company have been let down time and again. Some factors for the continued weakness in shares include: A poor acquisition, whereby the company acquired a portfolio of generic drugs from Teva and Allergan for $586 million, only to then take an impairment charge of $285.2 million after failing to calculate the extent of the price reductions it would have to make on the products it acquired to retain key clients.

Past Kidney Damage Linked to Pregnancy Problems

“We believe that this study highlights an important finding that will be useful for medical providers caring for reproductive-age women,” said study author Dr. Jessica Sheehan Tangren, a nephrologist from Massachusetts General Hospital in Boston. The researchers reviewed data from almost 25,000 women who gave birth at Massachusetts General Hospital between 1998 and 2007.

The Most Expensive Drugs of 2016

Prescription drug prices have gotten out of control for many Americans and many insurers, with some medications costing as much as premium sports cars, according to health-care investments analyst Keith Speights, writing for The Motley Fool. Speights recently reviewed the five most expensive drugs of 2016.